This initiative is designed to provide primary care clinicians and sleep
specialists with the information they need to assess and effectively treat
individuals with narcolepsy and/or excessive daytime sleepiness.
Ruth M. Benca, MD, PhD
Professor, Departments of Psychiatry and Psychology, and Committee on
Neuroscience
Associate Chair, Department of Psychiatry
University of Wisconsin School of Medicine and Public Health
Madison, WI
Consultant Fees: GlaxoSmithKline, sanofi-aventis U.S. LLC, Sepracor
Inc., Takeda Pharmaceuticals North America, Inc.
Honoraria: sanofi-aventis U.S. LLC, Sepracor Inc., Takeda
Pharmaceuticals North America, Inc.
Paul Doghramji, MD
Assistant Medical Director, Health Services
Ursinus College
Collegeville, PA
Advisory Boards: Cephalon, Inc., sanofi-aventis U.S. LLC, Takeda
Pharmaceuticals North America, Inc.
Honoraria: Cephalon, Inc., Pfizer Inc, sanofi-aventis U.S. LLC, Takeda
Pharmaceuticals North America, Inc.
Marc L. Gordon, MD
Chief of Neurology, the Zucker Hillside Hospital
Associate Professor of Clinical Neurology, Clinical Psychiatry, and Behavioral
Sciences
Department of Neurology
Albert Einstein College of Medicine
New Hyde Park, NY
Consultant Fees: Myriad Genetics, Inc., Teva Pharmaceuticals
Honoraria: EMD Serono/Pfizer, Myriad Genetics, Inc., Novartis
Pharmaceuticals Corporation, Ortho-McNeil Neurologics, Inc., Teva Neuroscience,
Joe Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Philadelphia, PA
Consultant Fees: AstraZeneca Pharmaceuticals LP, Pfizer Inc, Takeda
Pharmaceuticals North America, Inc.
Honoraria: sanofi-aventis U.S. LLC
Emmanuel Mignot, MD, PhD
Professor of Psychiatry and Behavioral Sciences
Stanford University
Stanford, CA
Consultant Fees: Jazz Pharmaceuticals, Inc.
Thomas Neylan, MD
Associate Professor of Psychiatry
University of California
San Francisco, CA
Consultant Fees: sanofi-aventis U.S. LLC, Sepracor Inc., Takeda
Pharmaceuticals North America, Inc.
Peter Aupperle, MD, MPH
Medical Director
The Chatham Institute
Chatham, NJ
No real or apparent conflicts of interest to report
Dan Duch, PhD
Scientific Director
The Chatham Institute
Chatham, NJ
No real or apparent conflicts of interest to report
After completing the educational activity,
participants should have an increased assessment of the:
-
Clinical and diagnostic characteristics of normal sleep and excessive daytime
sleepiness
-
Common causes of excessive daytime sleepiness, insomnia, and hypersomnia
-
Diagnostic criteria for breathing-related sleep disorder, circadian rhythm
sleep disorder, and narcolepsy
-
Evaluation of narcolepsy and sleep disorders related to other psychiatric or
medical diagnoses
It is the policy of The Chatham Institute to ensure balance, independence,
objectivity, and scientific rigor in all of its educational activities. All
faculty, planners, and managers who affect the content of medical education
activities sponsored by The Chatham Institute are required to disclose to the
audience any real or apparent conflict of interest related to the activity.
Faculty, planners, and managers not complying with the disclosure policy will
not be permitted to participate in this activity.
This program is sponsored by The Chatham Institute and supported through an
educational grant from Jazz Pharmaceuticals.
For
additional sleep-related educational activities, please click here